Sector Gamma AS Boosts Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Sector Gamma AS boosted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 29.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 137,714 shares of the medical equipment provider's stock after buying an additional 31,714 shares during the period. Zimmer Biomet accounts for approximately 5.0% of Sector Gamma AS's portfolio, making the stock its 6th biggest holding. Sector Gamma AS owned about 0.07% of Zimmer Biomet worth $14,547,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Dunhill Financial LLC increased its position in Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 218 shares during the last quarter. Stonebridge Financial Group LLC acquired a new stake in Zimmer Biomet in the 4th quarter valued at about $25,000. Brooklyn Investment Group purchased a new stake in Zimmer Biomet during the third quarter valued at about $35,000. Kentucky Trust Co purchased a new stake in shares of Zimmer Biomet in the fourth quarter worth approximately $39,000. Finally, OFI Invest Asset Management purchased a new position in Zimmer Biomet in the fourth quarter valued at about $40,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Trading Down 0.7 %

NYSE:ZBH traded down $0.74 on Tuesday, hitting $110.50. The stock had a trading volume of 1,296,857 shares, compared to its average volume of 1,497,421. The company has a fifty day moving average price of $106.98 and a two-hundred day moving average price of $106.90. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90. The stock has a market cap of $22.00 billion, a price-to-earnings ratio of 24.83, a PEG ratio of 1.95 and a beta of 1.04.

Remove Ads

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the previous year, the company posted $2.20 earnings per share. Equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date is Monday, March 31st. Zimmer Biomet's payout ratio is currently 21.57%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. JPMorgan Chase & Co. raised Zimmer Biomet from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Barclays decreased their price target on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research note on Monday, February 10th. JMP Securities reiterated a "market outperform" rating and issued a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, Stifel Nicolaus upped their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a research report on Thursday, January 23rd. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $124.15.

Insider Activity

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares of the company's stock, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.95% of the company's stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.